Research to develop life-saving products, including new vaccines and other products to protect against deadly drug-resistant bacterial infections, got a significant boost today.

The UK Government’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) and the Bill & Melinda Gates Foundation (BMGF) have joined the CARB-X partnership to support scientific research around the world to develop new vaccines, preventatives, and other products against drug-resistant bacterial infections, particularly among vulnerable populations in low- and middle-income countries.

New York State will invest $30 million into the Center for Bioelectronic Medicine at the Feinstein Institute for Medical Research in Manhasset as part of the state's $72 million investment to support three transformative, economic developments on Long Island, Gov. Andrew Cuomo announced Monday.

Results from a multi-year clinical trial testing hyperbaric oxygen as an intervention for US military service members who have experience mild traumatic brain injuries with persistent symptoms were published recently in Undersea and Hyperbaric Medicine Journal.

AI and Big Data allow innovators to leverage neuroscientific knowledge at scale to untapped markets.

We would all like our brains to be more powerful – especially those of us with reason to fear the effects of advancing age or a degenerative illness. For the entrepreneurs behind widely promoted “brain-training” apps like Lumosity, the universal desire for cognitive improvement translates to lucrative opportunities. Some scientists and clinicians, too, have hopped on the bandwagon, seeking avenues to lend their expertise to the business world while theoretically bringing cognitive enhancement to the masses.

BioHealth Innovation, Inc. (BHI) is a nonprofit organization focused on supporting BioHealth entrepreneurs and related industry growth in Montgomery County and the BioHealth Capital Region (Maryland, D.C. and Virginia).  BHI is seeking an energetic and motivated Marketing Intern to assist with communications and marketing-related projects. This position is estimated to be 15-25 hours per week, would start immediately, and continue for 12 weeks.  In addition to the responsibilities listed below, the intern may attend meetings and programs to understand the full work of BHI and how the organization accomplishes its mission through constituent outreach and support, commercialization and partnership activity.

StonebridgeCarras and The Donohoe Companies announced plans today for their project at 8280 Wisconsin Avenue which will focus its 175,000 square feet of commercial space on bringing life sciences to the Bethesda Central Business District (CBD).  StonebridgeCarras and Donohoe’s vision for the project is to capitalize on two converging trends:  employers locating their offices in live, work and play environments with access to mass transportation; and life sciences companies co-locating near thought leaders and institutions driving research and advancement.

Protenus has been selected by Modern Healthcare as one of the 2018 Best Places to Work in Healthcare. The complete list of this year’s winners, in alphabetical order, is available here. Modern Healthcare will publish a special supplement featuring ranked lists of all the winners along with the October 1 issue.

Paragon Bioservices, Inc. (Paragon), the leading private equity-backed biologics contract development and manufacturing organization (CDMO) with proven expertise in gene therapy and next-generation vaccines, was named the 2018 Life Science Company of the Year by the Maryland Tech Council (MTC). The announcement came at MTC’s 30th Annual Industry Awards held last night in the Hotel at the University of Maryland in College Park.

SoBran BioScience, a division of SoBran Inc, and a leading provider of pre-clinical GLP contract research announced the grand prize winner of the Innovation for Impact Prize sponsored in partnership with the Maryland Tech Council (MTC). This Grand Prize was awarded last night at the MTC 30th Anniversary Industry Awards Celebration.

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA approved Lokelma sodium zirconium cyclosilicate (ZS-9) to treat hyperkalemia in adults. AZ had received two CRLs for Lokelma following manufacturing concerns (see BioCentury Extra, March 17, 2017).

Enthusiasm for the biopharmaceutical sector in Asia has been flat, due in part to China’s market-access blockade, Japan’s spending controls, and deceleration in India and Southeast Asia. Recent changes have reignited interest in the region, with important implications for pharma executives.

A nonprofit organization, Knowledge Ecology International (KEI), recently filed a lawsuit against the National Institutes of Health (NIH) over Gilead Sciences’ patents for a new chimeric antigen receptor T-cell (CAR-T) therapy.

KEI calls itself a “not for profit non government organization that searches for better outcomes, including new solutions, to the management of knowledge resources. KEI is focused on social justice, particularly for the most vulnerable populations, including low-income persons and marginalized groups.”

The U.S. Small Business Administration, under its Federal and State Technology (FAST) Partnership Program, is soliciting grant applications from New York organizations to help boost the development of technology from small businesses.

Today the President of Iceland awarded Kerecis the Industry Award for Entrepreneurship. Kerecis is the creator, manufacturer and patent holder of revolutionary, fish-skin-based therapeutic products that speed up the healing process of human wounds and repair tissue damage. 

The Maryland Tech Council (MTC), Maryland’s largest technology trade association, announced the winners of its 30th Annual Industry Awards during a celebration and ceremony at The Hotel at the University of Maryland attended by more than 550 business leaders from around the state.

A complication from surgery can cost tens of thousands of dollars and require more surgery to correct — but a young Maryland startup is cooking up a more affordable and less invasive solution.

Maryland Technology Development Corp. has doled out $7.1 million to 25 companies and researchers working on stem cell products and medical therapies.

Venture development organizations (VDO), nonprofit organizations across the country investing in innovation startups to help grow their regional economies as well as earn a respectable return, saw at least 20 exits in the first quarter of 2018, based on data entered on Pitchbook.com. Here are some examples from the quarter:

Join the FLC on Tuesday, May 22 at 1:00 p.m. EDT for an inside look into these new regulations with NIST’s Courtney Silverthorn. To register for this webinar, visit http://connect.federallabs.org/new-t2-regulations-what-you-need-to-know. 

The Icahn School of Medicine at Mount Sinai has created a $10 million accelerator fund to speed up the commercialization of research at the school. It's starting with two investments in drug-development ventures.

The Small Business Innovation Research (SBIR) Program is an important funding mechanism that the National Institutes of Health (NIH) uses to develop innovative solutions that address public health challenges. A major objective of the SBIR Program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This Funding Opportunity Announcement (FOA) invites SBIR grant applications from SBCs to support later stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR Phase II awards and will require eventual Federal regulatory approval/clearance. The goal of this FOA and the resulting Phase IIB awards is to assist applicants in pursuing the milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between SBIR Phase II awardees and third-party investors and/or strategic partners.

The Small Business Innovation Research (SBIR) Program is an important National Institutes of Health (NIH) funding mechanism used to develop innovative solutions that address public health challenges. A major objective of the SBIR Program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This gap is increased by the barriers associated with technologies under development for small commercial markets, such as those focused on rare diseases or young pediatric populations. This Funding Opportunity Announcement (FOA) invites small businesses to submit SBIR grant applications to support later stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR (Small Business Technology Transfer) Phase II awards that address rare diseases or young pediatric populations (aged 0-12 years and defined in Section IV, part 7), and will require eventual Federal regulatory approval/clearance. The goal of this FOA and the resulting Phase IIB awards is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between small business awardees and third-party investors and/or strategic partners, including patient advocacy organizations.

Kite, a Gilead Company (Nasdaq: GILD), today announced it has leased a new facility in the Netherlands to engineer cell therapies in Europe. The 117,000 square-foot site in Hoofddorp (SEGRO Park Amsterdam Airport) will enable Kite to efficiently manufacture and deliver its cell therapies to people living with cancer in Europe and will provide more than 300 new jobs when fully operational in 2020.

Founders can become myopic during the long, stressful process of fundraising. Many focus solely on the amount of money they’re going to raise, their valuation, and the brand name of the investors they are pitching.

Tufts University has joined the biotech incubator craze, launching a coworking space in Boston earlier this year that organizers hope will foster another life sciences cluster in the heart of the city.

The MdBio Foundation, a non-profit that provides STEM education and workforce development to underserved communities, today announced that Katy Wnuk-Fink – a senior from Laurel who attends Reservoir High School – was named winner of the 2018 Maryland BioGENEius Challenge, the premier competition for high school students that recognizes outstanding original research in biotechnology for healthcare, sustainability, and the environment. As the Maryland BioGENEius finalist, Wnuk-Fink will represent the state in the International BioGENEius Challenge at the BIO International Convention in Boston in June.

Boston Children’s Hospital has teamed up with open-source solution provider Red Hat to create a web-based medical image platform that will speed the time it takes to share and analyze life-saving images.

Trying to build on Arizona’s significant investments in the life science discovery and healthcare delivery infrastructure, the state’s leaders are focused on bridging the funding gap that slows the growth of Arizona-based life science companies. Leaders of Arizona’s life science sector share a drive to accomplish a common goal: accelerate the growth of local companies that are developing and delivering innovative treatments that truly change lives.

This white paper takes an in depth look at trends in the pharmaceutical industry that are anticipated to make a significant impact on the sector in 2018. Industry professionals can leverage this information to make the course adjustments that will give their companies a competitive edge in the market.

A company that works to turn intellectual property into businesses is backing a new Johns Hopkins startup developing therapeutics to treat cancer.

New Enterprise Associates, one of Silicon Valley’s largest venture-capital firms, plans to sell off a big chunk of its startup investments in response to a dearth of initial public offerings, according to people familiar with the discussions.

Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, advances its ongoing Phase 2a study of RX-3117 in combination with Abraxane® in first-line patients with metastatic pancreatic cancer following a recently completed routine Safety Monitoring Committee (SMC) review.

MockV Solutions, Inc. (MockV or the Company), a company developing innovative products to analyze virus clearance during process development, announced today that it will be collaborating with the Vaccine Production Program of the Vaccine Research Center/National Institute of Allergy and Infectious Diseases/National Institutes of Health (VRC, NIAID, NIH) to evaluate its lead product candidate, the MVM-MVP Kit. The MVM-MVP Kit contains a non-infectious “Mock Virus Particle” (MVP) spiking surrogate that mimics the physicochemical characteristics of Minute Virus of Mice (MVM), a small and physiochemically resistant parvovirus, used as a universal standard for assessing viral clearance during process validation studies. The intention of this collaboration is to determine if the non-infectious MVP could be used as an accurate and economic indicator of MVM clearance during small scale bioprocess development studies.

The Iowa AgriTech Accelerator is a mentor-led accelerator focused on AgTech innovations. The Accelerator is led by innovators and leaders in several areas of agriculture, and seeks startups ready to change the status quo.

Intralytix, Inc., announced today that it has closed on the acquisition of a 33,000 sq. ft. building in Columbia, Maryland. The facility, located in the Columbia Gateway Community, will serve as the Company's new headquarters. Plans are underway to house expanded research and laboratory space, executive offices, and substantially increased manufacturing capacity.